Live Free or Die? New Hampshire Court Lifts Ban on Physician Prescribing Data
This article was originally published in RPM Report
Executive Summary
Pharmaceutical sales and marketing teams will have a much easier time selling their products in one US state-and may have avoided major restrictions in others across the country-after a New Hampshire law banning the use of physician prescribing data for commercial use was struck down in state court. But drug marketers will need to continue to keep an eye on a less restrictive program sponsored by the American Medical Association.
You may also be interested in...
Flying Blind: Learning to Live Without Physician Prescribing Data
Physicians aren't happy about the prescribing information companies use to help develop sales and marketing activities, and they're doing something about it. Policies adopted by medical professionals--and legislation moving at the state level--threaten to cut off marketers' access to information about who prescribes their products. Pharma companies better prepare to adapt to new ways of tracking sales.
Genentech’s Xeloda Is First Label Updated Under OCE’s ‘Project Renewal’
Capecitabine’s existing indications were revised and new indications added, reflecting uses that long have been considered standard of care; however, the cancer drug's label had been frozen in time since the approval of generics.
NDAs, BLAs To Start Getting KASA Quality Risk Assessments After Successful Pilot With ANDAs
Internal review system reduces US FDA’s administrative work for OPQ risk assessments; agency’s standards will not change, and sponsors will not need to modify applications. Advisory committee endorses expansion, which will roll out to different application types over several years.